Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

British Journal of Cancer

Volumn 90, Issue 5, 2004, Pages 955-961

  Bartlett, J B ^a   Michael, A ^a   Clarke, I A ^a   Dredge, K ^a   Nicholson, S ^a   Kristeleit, H ^a   Polychronis, A ^a   Pandha, H ^a   Muller, G W ^b   Stirling, D I ^b   Zeldis, J ^b   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CELGENE CORPORATION   (United States)

Author keywords

CC 5013; Cytokines; Immunomodulation; Phase I; T cell activation; Thalidomide

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; LENALIDOMIDE; LYMPHOCYTE SURFACE MARKER; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEMOPTYSIS; HOT FLUSH; HUMAN; IMMUNOSTIMULATION; JAUNDICE; LUNG COLLAPSE; MALE; MELANOMA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PAPULAR SKIN DISEASE; PARESTHESIA; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; SOMNOLENCE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TASTE DISORDER; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNIZATION; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASMS; SAFETY; SKIN NEOPLASMS; T-LYMPHOCYTES; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11144355748     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601579     Document Type: Article

References (40)

1. Alexander LN, Wilcox CM (1997) A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 13: 301-304
2. Armitage JO (1998) Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92: 4491-4508
3. Atkins MB (1997) The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 9: 205-213
4. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163: 380-386
5. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216
6. Dredge K, Marriott JB, Macdonald CD, Man H-W, Chen R, Muller GW, Stirling D, Dalgleish AG (2002a) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87: 1166-1172
7. Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002b) Protective anti-tumour immunity induced by a costimulatory thalidomide analog in conjunction with whole tumour cell vaccination is mediated by increased Th1-type immunity. J Immunol 168: 4914-4919
8. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB (1999) Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117: 1271-1277
9. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82: 812-817
10. Eisen T (2002) Thalidomide in solid malignancies. J Clin Oncol 20: 2607-2608
11. Fife K, Howard MR, Gracie F, Phillips RH, Bower M (1998) Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 9: 751-755
12. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708-715
13. Gutheil J, Finucane D (2000) Thalidomide therapy in refractory solid tumour patients. Br J Haematol 110: 754
14. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Silva A, Yurdakal S, Zwingenberger K, Yazici H (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128: 443-450
15. Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885-1892
16. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82: 1009-1012
17. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling D, Anderson KC (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950
18. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M., Wu AW, MacPhail LA, Vasquez GJ, Wohl DA (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 336: 1487-1493
19. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109: 89-96
20. Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, Dewar RL, Lane HC, Freedman VH, Kaplan G (1996) The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J AIDS 11: 247-257
21. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I (2000) Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br J Haematol 108: 391-393
22. Marriott JB, Muller G, Dalgleish AG (1999) Thalidomide as an emerging immunotherapeutic agent. Immunol Today 583: 538-540
23. Marriott JB, Muller GW, Stirling D, Dalgleish AG (2001) Immunotherapeutic and anti-tumour potential of thalidomide analogues. Exp Opin Biol Ther 1: 675-682
24. Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, Goldschmidt H (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115: 605-608
25. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Petersson JA, Waugh KA (2000) Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23: 319-321
26. Raje N, Anderson K (1999) Thalidomide - a revival story. N Engl J Med 341: 1606-1609
27. Reyes-Teran G, Sierra-Madero JG, Martinez Del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10: 1501-1507
28. Richardson PG, Schlossman RL, Hideshima T, Davies F, Le Blanc R, Catley L, Doss D, Kelly KA, McKennev M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo J, Chauhan D, Munshi N, Weller E, Thomas S, Zeldis J, Anderson KC (2001) A phase 1 study of oral CC-5013, an immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma. Presented at the American Society of Hematology 43rd Annual Meeting, Orlando, FL, 7-11 December
29. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley L, Doss D, Kelly KA, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo J, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067
30. Schuler U, Ehninger G (1995) Thalidomide: rationale for renewed use in immunological disorders. Drug Saf 12: 364-369
31. Sharpstone D, Rowbottom A, Nelson M, Gazzard B (1995) The treatment of microsporidial diarrhoea with thalidomide. AIDS 9: 658-659
32. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147
33. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddleman P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B (1999) Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
34. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte - macrophage colony-stimulating factor. J Clin Oncol 18: 1614-1621
35. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS (2001) Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92: 2364-2373
36. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan IR (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117: 1278-1287
37. Wettstein AR, Meagher AP (1997) Thalidomide in Crohn's disease. Lancet 350: 1445-1446
38. Youle M, Clarbour J, Farthing C, Connolly M, Hawkins D, Staughton R, Gazzard B (1989) Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ 298: 432
39. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B (2001) Results of phase 1 study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy. Presented at the American Society of Hematology 43rd Annual Meeting, Orlando, FL, 7-11 December
40. Zomas A, Anagnostopoulos N, Dimopoulos MA (2000) Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 25: 1319-1320